<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651702</url>
  </required_header>
  <id_info>
    <org_study_id>0067-12-RMC</org_study_id>
    <nct_id>NCT01651702</nct_id>
  </id_info>
  <brief_title>Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations</brief_title>
  <official_title>Comparative Study of Two 3D Electroanatomical Mapping Systems for Ablations of Different Complex Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three dimensional anatomical mapping is an established method facilitating ablation of&#xD;
      cardiac arrhythmias. The most commonly used systems are CARTO® System (Biosense Webster,&#xD;
      Inc., Diamond Bar, CA, USA) and EnSite NavX™ (St. Jude Medical, Inc., St. Paul, MN, USA).&#xD;
      These two systems has been compared in only a few studies. Recent technical advances resulted&#xD;
      in the development of new versions of both systems. To the best of the investigators&#xD;
      knowledge no studies have been performed for direct comparison of the newer versions of these&#xD;
      two systems. The aim of the study to compare two systems for the use in the ablation of&#xD;
      complex arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Three dimensional anatomical mapping is an established method facilitating ablation of&#xD;
      cardiac arrhythmias. It is nowadays an excepted method especially for complex arrhythmias&#xD;
      such as atrial fibrillation and ventricular tachycardia.&#xD;
&#xD;
      The most commonly used systems are CARTO® System (Biosense Webster, Inc., Diamond Bar, CA,&#xD;
      USA) and EnSite NavX™ (St. Jude Medical, Inc., St. Paul, MN, USA). These mapping systems have&#xD;
      helped to decrease procedural complexity, procedure time, and improve safety. The EnSite NavX&#xD;
      system uses impedance measurements between the individual catheter electrodes and the patches&#xD;
      placed on the patient's chest and abdomen. The CARTO system utilizes magnetic location&#xD;
      technology to provide accurate visualization of the magnet sensor-equipped catheter tip.&#xD;
&#xD;
      These two systems has been compared in only a few studies. Different results have been found&#xD;
      in simple ablations versus more complex ablation of atrial fibrillation. Recent technical&#xD;
      advances resulted in the development of new versions of both systems. Carto Express version&#xD;
      allows quicker mapping and reconstruction of heart cavities and great vessels geometry as&#xD;
      compared to previous versions of Carto XP. EnSite Velocity system incorporates more precise&#xD;
      catheter visualization, and allows quicker mapping as compared to previous version of EnSite.&#xD;
&#xD;
      To the best of the investigators knowledge no studies have been performed for direct&#xD;
      comparison of the newer versions of these two systems.&#xD;
&#xD;
      Study design Prospective single-center non-randomized open label comparison study. Primary&#xD;
      objective Comparison of Carto Express system vs. EnSite Velocity system for ablation of&#xD;
      complex arrhythmias.&#xD;
&#xD;
      End points:&#xD;
&#xD;
        1. Procedure duration.&#xD;
&#xD;
        2. Fluoroscopy time&#xD;
&#xD;
        3. Procedure success -will be measured in terms of the 1-year recurrent arrhythmia rate&#xD;
           Study population Patients planned for ablation of complex arrhythmia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Poor recruit rate&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>Procedure duration - average expected 2.5 hours</time_frame>
    <description>Average procedure duration (needle to catheters withdrawal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Procedures will be evaluated for the fluoro time, expected average 30 min</time_frame>
    <description>Average fluro time in each of groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>Patients will be followed for one year for recurrency of arrhythmia</time_frame>
    <description>Recurrency of the arrhythmia assessed by blinded electrophysiologist</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Carto</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in whom Carto system will be used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ensite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in whom Ensite system will be used</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carto</intervention_name>
    <description>Group of patients where Carto Express system will be used for electroanatomical mapping.</description>
    <arm_group_label>Carto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ensite</intervention_name>
    <description>Group of patients where Ensite Velocity system will be used for electroanatomical mapping.</description>
    <arm_group_label>Ensite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18- 80.&#xD;
&#xD;
          2. Ability to sign informed consent.&#xD;
&#xD;
          3. History of one of the following arrhythmias requiring the use of 3D electroanatomical&#xD;
             mapping:&#xD;
&#xD;
               -  Symptomatic paroxysmal or persistent atrial fibrillation with failed treatment of&#xD;
                  at least two anti-arrhythmic drugs.&#xD;
&#xD;
               -  Ischemic ventricular tachycardia necessitating ablation as per decision of&#xD;
                  electrophysiologist.&#xD;
&#xD;
               -  Symptomatic atrial tachycardia after failed medical treatment.&#xD;
&#xD;
               -  Symptomatic idiopathic ventricular tachycardia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable patients not allowing performing procedure more than 2 hours&#xD;
&#xD;
          2. Patients planned for one of the two systems compared for whatever reason Ex. procedure&#xD;
             planned with NAVX system Array Balloon).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Golovchiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Gregory Golovchiner, MD</investigator_full_name>
    <investigator_title>Principle Invistigator</investigator_title>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Electroanatomical mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

